The findings of previous studies have shown that LOXL2 is highly expressed in a variety of cancers in humans including head and neck squamous cell carcinoma, breast, colon, skin, and gastric cancer, and its high expression correlates with metastasis and poor prognosis23,34–37. Here, LOXL2 is linked to head and neck squamous cell carcinoma.